- Home
- VTLE vs TBPH Comparison
VTLE vs TBPH Comparison
Compare VTLE & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTLE
- TBPH
- Stock Information
- Founded
- VTLE 2006
- TBPH 2013
- Country
- VTLE United States
- TBPH United States
- Employees
- VTLE N/A
- TBPH N/A
- Industry
- VTLE
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- VTLE
- TBPH Health Care
- Exchange
- VTLE Nasdaq
- TBPH Nasdaq
- Market Cap
- VTLE 678.2M
- TBPH 699.0M
- IPO Year
- VTLE 2011
- TBPH N/A
- Fundamental
- Price
- VTLE $17.89
- TBPH $20.16
- Analyst Decision
- VTLE Hold
- TBPH Strong Buy
- Analyst Count
- VTLE 11
- TBPH 4
- Target Price
- VTLE $25.78
- TBPH $24.25
- AVG Volume (30 Days)
- VTLE 533.2K
- TBPH 569.5K
- Earning Date
- VTLE 11-03-2025
- TBPH 11-10-2025
- Dividend Yield
- VTLE N/A
- TBPH N/A
- EPS Growth
- VTLE N/A
- TBPH N/A
- EPS
- VTLE N/A
- TBPH 0.58
- Revenue
- VTLE $1,897,003,000.00
- TBPH $80,327,000.00
- Revenue This Year
- VTLE $0.55
- TBPH $79.82
- Revenue Next Year
- VTLE N/A
- TBPH N/A
- P/E Ratio
- VTLE N/A
- TBPH $32.54
- Revenue Growth
- VTLE 1.85
- TBPH 27.12
- 52 Week Low
- VTLE $12.30
- TBPH $7.90
- 52 Week High
- VTLE $36.72
- TBPH $18.96
- Technical
- Relative Strength Index (RSI)
- VTLE 59.01
- TBPH 74.02
- Support Level
- VTLE $15.56
- TBPH $17.50
- Resistance Level
- VTLE $17.57
- TBPH $18.58
- Average True Range (ATR)
- VTLE 1.01
- TBPH 1.03
- MACD
- VTLE 0.09
- TBPH 0.23
- Stochastic Oscillator
- VTLE 78.18
- TBPH 98.01
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).